Trial · NCT01277744
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
NCT01277744, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2019-10-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor. Trials, record NCT01277744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01277744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
- NCT number
- NCT01277744
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Advanced Cancers, Sarcoma
- Interventions
- Hyperthermic Peritoneal Perfusion (HIPEC), Cisplatin
- First posted
- 2011-01-17
- Last updated
- 2020-01-13
- Results first posted
- 2019-10-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence Free Survival | 36 months after the last participant enrolled | Date of surgery to date of death or date of recurrence, whichever occurred first for patients who experienced an event, and to date of last follow-up for patients alive without recurrence |
| Secondary | Overall Survival | From the date of diagnosis to the date of death or last follow up date for patient alive up to 81 months | From the date of diagnosis to the date of death or last follow up date for patient alive. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Recurrence Free Survival | 36 months after the last participant enrolled | months | MEDIAN | |
| SECONDARY | Overall Survival | From the date of diagnosis to the date of death or last follow up date for patient alive up to 81 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recurrence Free Survival | HIPEC | 13.99 | 95% Confidence Interval 7.26 to NA | months | |
| Overall Survival | HIPEC | 58.4 | 95% Confidence Interval 43.7 to NA | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | HIPEC | 22 | |
| Overall Study | COMPLETED | HIPEC | 20 | |
| Overall Study | NOT COMPLETED | HIPEC | 2 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Creatinine increased | Investigations | HIPEC | 2 | 20 | |
| other | White blood cell decreased | Investigations | HIPEC | 14 | 20 | |
| other | Platelet count decreased | Investigations | HIPEC | 15 | 20 | |
| other | Neurogenic bladder | Gastrointestinal disorders | HIPEC | 3 | 20 | |
| other | Urinary tract infection | Infections and infestations | HIPEC | 2 | 20 | |
| other | Wound infection | Infections and infestations | HIPEC | 1 | 20 | |
| other | Enterocutaneous fistula | Gastrointestinal disorders | HIPEC | 1 | 20 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | HIPEC | 0 | 20 |
| Total, other adverse events | HIPEC | 18 | 20 |
| Total, serious adverse events | HIPEC | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01277744
GET https://conductscience.org/api/trials/v1/NCT01277744/registered